As part of the restructure, the full service contract research organisation (CRO) has announced its Durham, North Carolina office will become its US headquarters, with its current New Jersey office set to close. At the same time, the firm is branching out on both the East and West coast.
“Cmed is placing offices in Boston and San Francisco to allow us to be more closely geographically aligned with many of our clients who have their clinical development teams based in these locations,” spokesperson Anna Forster told Outsourcing-Pharma.com.
“Boston and San Francisco continue to be the main centres of both Pharma and Biotech early phase/ POC sponsor activity,” where many of the firm’s clients are located she added. “Cmed sees increasing demand for our services with repeat business, new clients and an increasing number of Requests for Proposals (RFPs).”
For Cmed, initial services the new sites will offer include Project Management and Business Development, with other functions being added as needed, according to Forster.
As well as offering full clinical trial services, the company provides an eClinical technology platform called Timaeus, “an advanced data capture, management and reporting platform which enables fast database build and deployment” Forster added.
Within the last two months, CRO Valesco Pharma has opened an office in the greater Boston area, whilst European CRO The Clinical Trial Company has expanded its footprint to San Francisco.
Furthermore, Cmed’s decision to move its headquarters to North Carolina puts it in good company with some of the biggest CROs who have set up a global home in the State, including Quintiles, PRA, INC Research and Novella Clinical.